Prestige Consumer Healthcare Inc. (PBH) stock
PBHNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 12/3025% below fair value
$49.06+0.31 (+0.64%)
Close on Oct 30, 2026Market cap $2.32BP/E 13.7Yield –
Earnings
Prestige Consumer Healthcare's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 5, 2026
Q2 FY2027 · estimated, before the open
Revenue, Q1 FY2027
$265.70M
+6.5% on a year earlier
Adjusted Diluted EPS, Q1 FY2027
$0.98
$0.95 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 3 items
Quarterly results
Revenue and earnings per share from each of Prestige Consumer Healthcare's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q2 FY2027ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – | – |
| Q1 FY2027ended Jun 30, 2026 | Aug 6, 2026before the open | $265.70M | +6.5% | $0.61 | $0.98 | Release |
| Q4 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | $281.60M | -5.0% | $1.13 | $1.23 | Release |
| Q3 FY2026ended Dec 31, 2025 | Feb 5, 2026before the open | $283.40M | -2.4% | $0.97 | $1.14 | Release |
| Q2 FY2026ended Sep 30, 2025 | Nov 6, 2025before the open | $274.10M | -3.4% | $0.86 | $1.07 | Release |
| Q1 FY2026ended Jun 30, 2025 | Aug 7, 2025before the open | $249.50M | -6.6% | $0.95 | – | Release |
| Q4 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $296.50M | +7.0% | $1.00 | $1.32 | Release |
| Q3 FY2025ended Dec 31, 2024 | Feb 6, 2025before the open | $290.30M | +2.7% | $1.22 | $1.22 | Release |
| Q2 FY2025ended Sep 30, 2024 | Nov 7, 2024before the open | $283.80M | -0.9% | $1.09 | $1.09 | Release |
| Q1 FY2025ended Jun 30, 2024 | Aug 8, 2024before the open | $267.10M | -4.4% | $0.98 | $0.90 | Release |
| Q4 FY2024ended Mar 31, 2024 | May 14, 2024during market hours | $277.00M | -3.1% | $0.98 | $1.02 | Release |
| Q3 FY2024ended Dec 31, 2023 | Feb 8, 2024before the open | $282.70M | +2.6% | $1.06 | – | Release |
| Q2 FY2024ended Sep 30, 2023 | Nov 2, 2023before the open | $286.30M | -1.0% | $1.07 | – | Release |
| Q1 FY2024ended Jun 30, 2023 | Aug 3, 2023before the open | $279.30M | +0.8% | $1.06 | – | Release |
| Q4 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $285.90M | +7.1% | -$4.83 | $1.07 | Release |
| Q3 FY2023ended Dec 31, 2022 | Feb 2, 2023before the open | $275.50M | +0.4% | $1.04 | $1.04 | Release |
| Q2 FY2023ended Sep 30, 2022 | Nov 3, 2022before the open | $289.30M | +4.7% | $1.02 | $1.02 | Release |
| Q1 FY2023ended Jun 30, 2022 | Aug 4, 2022before the open | $277.10M | – | $1.09 | – | Release |
| Q4 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $266.90M | – | $1.02 | $0.91 | Release |
| Q3 FY2022ended Dec 31, 2021 | Feb 3, 2022before the open | $274.50M | – | $0.99 | $0.99 | Release |
| Q2 FY2022ended Sep 30, 2021 | Nov 4, 2021before the open | $276.20M | – | $0.89 | $1.02 | Release |
| Q1 FY2022ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q4 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q3 FY2021ended Dec 31, 2020 | Feb 4, 2021before the open | – | – | – | – | Filing |
| Q2 FY2021ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
| Q1 FY2021ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Prestige Consumer Healthcare's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Organic Revenue Growthnon-GAAP | FY2027 | +1% – +3% | – | New | May 13, 2026 |
| Revenue | FY2027 | $1.10B – $1.12B | – | New | May 13, 2026 |
| Projected FY'27 GAAP Diluted EPSGAAP | FY2027 | $4.18 – $4.28 | $4.31 – $4.40 | Lowered | Aug 6, 2026 |
| Adjusted Diluted E.P.S.non-GAAP | FY2027 | $4.42 – $4.51 | – | New | May 13, 2026 |
| Projected FY'27 Non-GAAP Free Cash Flownon-GAAP | FY2027 | $251.00M | $250.00M | Raised | Aug 6, 2026 |
| Additions to property and equipment for cashGAAP | FY2027 | $26.00M | – | New | May 13, 2026 |
| Projected FY'27 GAAP Net cash provided by operating activitiesGAAP | FY2027 | $277.00M | $268.00M | Raised | Aug 6, 2026 |
Guidance vs results
The last range Prestige Consumer Healthcare gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2026 | EPS (GAAP) | $4.33 – $4.37 | $3.91Σ4Q | Below range |
| FY2026 | Revenue | $1.10B | $1.09BΣ4Q | Below range |
| FY2025 | Adjusted Diluted E.P.S. | $4.50 | $4.53Σ4Q | Above range |
| FY2025 | EPS (GAAP) | $4.58 | $4.29Σ4Q | Below range |
| FY2025 | Revenue | $1.13B – $1.13B | $1.14BΣ4Q | Above range |
Guidance history
Every forecast Prestige Consumer Healthcare put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 6, 2026 | Projected FY'27 GAAP Diluted EPS | FY2027 | $4.18 – $4.28 | Lowered |
| Aug 6, 2026 | Projected FY'27 Non-GAAP Free Cash Flow | FY2027 | $251.00M | Raised |
| Aug 6, 2026 | Projected FY'27 GAAP Net cash provided by operating activities | FY2027 | $277.00M | Raised |
| May 13, 2026 | Additions to property and equipment for cash | FY2027 | $26.00M | New |
| May 13, 2026 | Adjusted Diluted E.P.S. | FY2027 | $4.42 – $4.51 | New |
| May 13, 2026 | Projected FY'27 GAAP Diluted EPS | FY2027 | $4.31 – $4.40 | New |
| May 13, 2026 | Projected FY'27 Non-GAAP Adjusted Free Cash Flow | FY2027 | $250.00M | New |
| May 13, 2026 | Projected FY'27 Non-GAAP Free Cash Flow | FY2027 | $242.00M | Lowered |
| May 13, 2026 | Projected FY'27 GAAP Net cash provided by operating activities | FY2027 | $268.00M | New |
| May 13, 2026 | Organic Revenue Growth | FY2027 | +1% – +3% | New |
| May 13, 2026 | Revenue | FY2027 | $1.10B – $1.12B | New |
| Feb 5, 2026 | Adjusted Diluted E.P.S. | FY2026 | $4.54 | Lowered |
| Feb 5, 2026 | Free Cash Flow | FY2026 | $245.00M | Reaffirmed |
| Feb 5, 2026 | Organic Revenue Growth | FY2026 | +3% | New |
| Feb 5, 2026 | Revenue | FY2026 | $1.10B | Lowered |
| Nov 6, 2025 | Adjusted Diluted EPS | FY2026 | $4.54 – $4.58 | New |
| Nov 6, 2025 | Projected FY'26 GAAP Diluted EPS | FY2026 | $4.33 – $4.37 | Lowered |
| Nov 6, 2025 | Free Cash Flow | FY2026 | $245.00M | Reaffirmed |
| Nov 6, 2025 | Projected GAAP Net cash provided by operating activities | FY2026 | $255.00M | Reaffirmed |
| Nov 6, 2025 | Organic Revenue Growth | FY2026 | -3% – -1.5% | Lowered |
| Nov 6, 2025 | Revenue | FY2026 | $1.10B – $1.12B | Lowered |
| Aug 7, 2025 | Diluted EPS | FY2026 | $4.50 – $4.58 | New |
| Aug 7, 2025 | free cash flow | FY2026 | $245.00M | Reaffirmed |
| Aug 7, 2025 | revenue | FY2026 | $1.10B – $1.12B | New |
| May 8, 2025 | Additions to property and equipment for cash | FY2026 | $10.00M | New |
| May 8, 2025 | Diluted E.P.S. | FY2026 | $4.70 – $4.82 | New |
| May 8, 2025 | Free Cash Flow | FY2026 | $245.00M | New |
| May 8, 2025 | Projected FY'26 GAAP Net cash provided by operating activities | FY2026 | $255.00M | New |
| May 8, 2025 | Organic Revenue Growth | FY2026 | +1% – +2% | New |
| May 8, 2025 | Revenue | FY2026 | $1.14B – $1.16B | New |
| Feb 6, 2025 | Adjusted Diluted E.P.S. | FY2025 | $4.50 | New |
| Feb 6, 2025 | Projected FY'25 GAAP Diluted EPS | FY2025 | $4.58 | New |
| Feb 6, 2025 | Free Cash Flow | FY2025 | $240.00M | New |
| Feb 6, 2025 | Organic Revenue Growth | FY2025 | +1% | New |
| Feb 6, 2025 | Projected FY'25 GAAP Net cash provided by operating activities | FY2025 | $250.00M | New |
| Feb 6, 2025 | Revenue | FY2025 | $1.13B – $1.13B | New |
| Nov 7, 2024 | Adjusted Diluted E.P.S. | FY2025 | $4.40 – $4.46 | Reaffirmed |
| Nov 7, 2024 | Projected FY'25 GAAP Diluted EPS | FY2025 | $4.48 – $4.54 | Reaffirmed |
| Nov 7, 2024 | Free Cash Flow | FY2025 | $240.00M | Reaffirmed |
| Nov 7, 2024 | Organic Revenue Growth | FY2025 | +1% | New |
| Nov 7, 2024 | Projected FY'25 GAAP Net cash provided by operating activities | FY2025 | $250.00M | New |
| Nov 7, 2024 | Revenue | FY2025 | $1.13B – $1.14B | New |
| Aug 8, 2024 | Adjusted Diluted E.P.S. | FY2025 | $4.40 – $4.46 | New |
| Aug 8, 2024 | Projected FY'25 GAAP Diluted EPS | FY2025 | $4.48 – $4.54 | Raised |
| Aug 8, 2024 | Free Cash Flow | FY2025 | $240.00M | Reaffirmed |
| Aug 8, 2024 | Organic Revenue Growth | FY2025 | +1% | Reaffirmed |
| Aug 8, 2024 | Revenue | FY2025 | $1.13B – $1.14B | Reaffirmed |
| May 14, 2024 | Diluted E.P.S. | FY2025 | $4.40 – $4.46 | New |
| May 14, 2024 | Free Cash Flow | FY2025 | $240.00M | New |
| May 14, 2024 | Revenue | FY2025 | $1.13B – $1.14B | New |
| May 14, 2024 | Organic Revenue Growth | FY2025 | +1% | New |
| Feb 8, 2024 | Diluted E.P.S. | FY2024 | $4.33 | Raised |
| Feb 8, 2024 | Free Cash Flow | FY2024 | $240.00M | Reaffirmed |
| Feb 8, 2024 | Organic Revenue Growth | FY2024 | +1% – +2% | Reaffirmed |
| Feb 8, 2024 | Revenue | FY2024 | $1.14B – $1.14B | Reaffirmed |
| Nov 2, 2023 | Diluted E.P.S. | FY2024 | $4.27 – $4.32 | Reaffirmed |
| Nov 2, 2023 | Free Cash Flow | FY2024 | $240.00M | Reaffirmed |
| Nov 2, 2023 | Revenue | FY2024 | $1.14B – $1.14B | Reaffirmed |
| Nov 2, 2023 | Organic Revenue Growth | FY2024 | +1% – +2% | Reaffirmed |
| Aug 3, 2023 | Diluted E.P.S. | FY2024 | $4.27 – $4.32 | New |
| Aug 3, 2023 | Free Cash Flow | FY2024 | $240.00M | Reaffirmed |
| Aug 3, 2023 | Organic Revenue Growth | FY2024 | +1% – +2% | Reaffirmed |
| Aug 3, 2023 | Revenue | FY2024 | $1.14B – $1.14B | New |
| May 4, 2023 | Diluted E.P.S. | FY2024 | $4.27 – $4.32 | New |
| May 4, 2023 | Free Cash Flow | FY2024 | $240.00M | New |
| May 4, 2023 | Organic Revenue Growth | FY2024 | +1% – +2% | New |
| May 4, 2023 | Revenue | FY2024 | $1.14B – $1.14B | New |
| Feb 2, 2023 | Diluted E.P.S. | FY2023 | $4.18 | Lowered |
| Feb 2, 2023 | Free Cash Flow | FY2023 | $220.00M | Lowered |
| Feb 2, 2023 | Revenue | FY2023 | $1.12B – $1.12B | Lowered |
| Feb 2, 2023 | Organic Revenue Growth | FY2023 | +3% | Raised |
| Nov 3, 2022 | Diluted E.P.S. | FY2023 | $4.18 – $4.23 | Reaffirmed |
| Nov 3, 2022 | Free Cash Flow | FY2023 | $260.00M | Reaffirmed |
| Nov 3, 2022 | Revenue | FY2023 | $1.12B – $1.13B | Reaffirmed |
| Nov 3, 2022 | Organic Revenue Growth | FY2023 | +2% – +3% | Reaffirmed |
| Aug 4, 2022 | Diluted E.P.S. | FY2023 | $4.18 – $4.23 | Reaffirmed |
| Aug 4, 2022 | Free Cash Flow | FY2023 | $260.00M | Reaffirmed |
| Aug 4, 2022 | Revenue | FY2023 | $1.12B – $1.13B | Reaffirmed |
| Aug 4, 2022 | Organic Revenue Growth | FY2023 | +2% – +3% | Reaffirmed |
| May 5, 2022 | Diluted E.P.S. | FY2023 | $4.18 – $4.23 | New |
| May 5, 2022 | Free Cash Flow | FY2023 | $260.00M | New |
| May 5, 2022 | Organic Revenue Growth | FY2023 | +2% – +3% | New |
| May 5, 2022 | Revenue | FY2023 | $1.12B – $1.13B | New |
| Feb 3, 2022 | Adjusted Diluted E.P.S. | FY2022 | $4.00 – $4.04 | Raised |
| Feb 3, 2022 | Projected FY'22 GAAP Diluted EPS | FY2022 | $3.87 – $3.91 | Raised |
| Feb 3, 2022 | Adjusted Free Cash Flow | FY2022 | $250.00M | Raised |
| Feb 3, 2022 | Organic Growth | FY2022 | +9% | New |
| Feb 3, 2022 | Revenue | FY2022 | $1.08B – $1.08B | Raised |
| Nov 4, 2021 | Adjusted Diluted E.P.S. | FY2022 | $3.93 – $3.98 | New |
| Nov 4, 2021 | Projected FY'22 GAAP Diluted EPS | FY2022 | $3.80 – $3.85 | New |
| Nov 4, 2021 | Adjusted Free Cash Flow | FY2022 | $245.00M | New |
| Nov 4, 2021 | Revenue | FY2022 | $1.05B – $1.06B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Prestige Consumer Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- News
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results